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ABSTRACT
Melanoma is a deadly form of malignancy and according to the World Health 
Organization 132,000 new cases of melanoma are diagnosed worldwide each year. 
Surgical resection and chemo/drug treatments opted for early and late stage of 
melanoma respectively, however detrimental post surgical and chemotherapy 
consequences are inevitable. Noticeably melanoma drug treatments are associated 
with liver injuries such as hepatitis and cholestasis which are very common. Alleviation 
of these clinical manifestations with better treatment options would enhance prognosis 
status and patients survival. Natural products which induce cytotoxicity with minimum 
side effects are of interest to achieve high therapeutic efficiency. In this study we 
investigated anti-melanoma and hepatoprotective activities of frankincense essential 
oil (FEO) in both in vitro and in vivo models. Pretreatment with FEO induce a significant 
(p < 0.05) dose-dependent reduction in the cell viability of mouse (B16-F10) and 
human melanoma (FM94) but not in the normal human epithelial melanocytes 
(HNEM). Immunoblot analysis showed that FEO induces down regulation of Bcl-2 
and up regulation of BAX in B16-F10 cells whereas in FM94 cells FEO induced dose-
dependent cleavage of caspase 3, caspase 9 and PARP. Furthermore, FEO (10 µg/ml) 
treatment down regulated MCL1 in a time-dependent manner in FM94 cells. In vivo 
toxicity analysis reveals that weekly single dose of FEO (1200 mg/kg body weight) did 
not elicit detrimental effect on body weight during four weeks of experimental period. 
Histology of tissue sections also indicated that there were no observable histopathologic 
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INTRODUCTION
Melanoma is one of the most aggressive forms of 
skin cancer with a high frequency of metastasis and a poor 
prognosis in the metastatic stage [1]. About 132,000 new 
cases of melanoma are diagnosed worldwide each year, 
according to the World Health Organization. Incidence 
rates are higher in women than in men before the age of 
50, but by the age of 65, rates in men are double those 
in women, and by age 80 they are triple [2]. Despite 
advances in surgery and multi-agent chemotherapy, nearly 
80% of patients still die from metastatic melanoma [3]. 
BRAF inhibitor and interleukin 2 therapy are often used 
in clinical set up but these regimens elicit severe toxicities 
with unsatisfactory efficacy and rapid development of 
resistance [4–6]. If patients were diagnosed early with 
primary melanoma, surgical resection is the best choice for 
most of them to reduce mortality [7]. However, a 5-year 
survival rate in metastatic melanoma is still under 15–20% 
of patients [8]. Clinicians prefer chemotherapy as a first 
line treatment option to avoid surgical consequences. 
High doses of chemotherapy are prescribed depending on 
the stage of melanoma but drug tolerance level of system 
is questionable. Conventional chemotherapy dosing 
schedule is used to balance the toxicity and efficacy, but 
the severe side effects in particular hepatotoxicity limits 
the administration of most anticancer agents [9]. Liver 
is the vital organ responsible for detoxification of drugs, 
however exposure of multiple doses of drugs leads to 
cholestatic hepatitis, progression to fibrosis and cirrhosis, 
malignant transformation, sinusoidal obstruction and 
fulminant hepatic failure [10–12]. Melanoma treatment is 
associated with liver injury. Ipilimumab and nivolumab 
well known target agents were approved by WHO to 
treat different stages of melanoma. Tanaka et al. reported 
that administration of both ipilimumab and nivolumab 
to 59 year old stage IV melanoma patients elicits severe 
hepatitis and elevation of liver injury associated serum 
biomarkers [13, 14]. This evidence alarms the urgent need 
of a safer alternative therapeutic regimen for melanoma. 
Natural products (extracts or pure compounds) 
from various sources (plants, marine organisms, 
microorganisms, etc) are screened for their ability to act 
as anti-tumor agents and have shown to have structural 
diversity and chemical complexity, as well as modulating 
several cellular signaling pathways [15]. Reportedly, 
natural products activate anti-inflammatory, anti-tumor 
and/or anti-metastatic responses [15, 16] and also evade 
multidrug resistance [17, 18]. Vinblastine and paclitaxel, 
are well known anti cancer agents obtained from natural 
sources. Frankincense is an aromatic resin hardened from 
exuded gums obtained from trees of the genus Boswellia 
(Burseraceae family). Boswellia sp. includes Boswellia 
sacra from Oman and Yemen, Boswellia carteri from 
Somalia, and Boswellia serrata from India and China. 
It has been commonly used to reduce swelling and 
alleviate the pain of inflammatory diseases or tumors 
[19, 20]. Frankincense extract has been used in China for 
its accelerating effects on blood circulation. It has been 
used as an antiarthritic in ayuredic medicine in India 
for thousands of years [19]. Winking et al. reported that 
a frankincense extract induces apoptosis and prolong 
survival in a rat glioma model [21]. A methanol extract of 
Boswellia serrata inhibits abnormal skin cell proliferation 
induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) 
and tumor promotion initiated by 7,12-dimethylbenz[a]
anthracene (DMBA) in a mouse model [22]. In a human 
clinical study, a Boswellia serrata resin extract has been 
shown to reduce cerebral edema and potential anti-
cancer activity in patients irradiated for brain tumors 
[23]. Boswellia sp. essential oil, an extract prepared by 
distillation of frankincense gum resins, is one of the 
most commonly used essential oils in aromatherapy 
and it is reported as potent anti-cancer agent in breast 
and pancreatic cancer models [24, 25]. Previously, we 
reported an anti-cancer activity induced by heavy terpenes 
extracted from frankincense in breast cancer model [26]. 
These evidences strongly suggests the anti-tumor potential 
of frankincense, however, the efficacy of frankincense 
essential oil on melanoma is not yet reported. In this 
study we assessed the effect of frankincense essential 
oil on in vitro and in vivo model of melanoma. Further 
experiments were also carried out to investigate its 
potential hepatoprotective efficacy.
differences in the brain, heart, liver, and kidney compare to control groups. FEO (300 
and 600 mg/kg body weight) treatments significantly reduced the tumor burden in 
C57BL/6 mice melanoma model. Acetaminophen (750 mg/kg body weight) was used to 
induce hepatic injury in Swiss albino mice. Pre treatment with FEO (250 and 500 mg/kg 
body weight) for seven days retained hematology (complete blood count), biochemical 
parameters (AST, ALT, ALK, total bilirubin, total protein, glucose, albumin/globulin 
ratio, cholesterol and triglyceride), and the level of phase I and II drug metabolizing 
enzymes (cytochrome P450, cytochromeb5, glutathione-S-transferase)  which were 
obstructed by the administration of acetaminophen. Further liver histology showed 
that FEO treatments reversed the damages (central vein dilation, hemorrhage, and 
nuclei condensation) caused by acetaminophen. In conclusion, FEO elicited marked 
anti-melanoma in both in vitro and in vivo with a significant heptoprotection.
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RESULTS
Cell viability
B16-F10 and FM94 cells were treated with FEO at 
3, 5, 7 and 10 µg/ml for 24 h. FEO induced reduction in 
the cell viability of B16-F10 and FM94 carcinoma cells 
as  compare to  the untreated control (Figure 1A and 1B) 
and not normal human epithelial melanocyte (HNEM) 
(Figure 1C). FEO treated FM94 cells completely lost their 
adherence and morphology whereas HNEM cells retained 
their morphology (Figure 1D and 1E). The data indicated 
that pre treatment with FEO induced cytotoxicity in tumor 
cells by sparing normal cells.
Nuclear fragmentation
24 h of FEO treatment induced apoptosis in B16-F10 
cells. Hoechest staining reveals that 5, 7 and 10 µg/ml 
of FEO induced nuclear fragmentation when compared 
to untreated control (Figure 2). These data indicate that 
FEO constituents target the nucleus of melanoma cells and 
cause DNA damage.
DNA fragmentation 
To ensure the DNA targeting ability of FEO, 
B16-F10 cells were treated with different concentrations 
(5, 7 and 10 µg/ml) of FEO for 24 hrs and observed for 
DNA damage. Figure 3 shows that FEO induced DNA 
ladder formation in dose-dependent manner. 
 Apoptosis 
B16-F10 cells were treated with FEO at 10 μg/ml 
for 24 h and analyzed for apoptosis by annexin V 
staining using flow cytometry. FEO treatment resulted 
in a significant increase in percentage of cells in early 
(25%) and late (10%) apoptotic stage whereas only 2–3% 
of untreated cells reached early and late apoptosis stage 
(Figure 4). 
Molecular mechanism of inducing apoptosis by 
FEO
To determine the mechanism of apoptotic induction 
in B16-F10 cells by FEO treatment, the expression 
levels of Bcl-2 and Bax by western blot were analyzed. 
The immunoblot analysis showed gradual decline in the 
expression levels of Bcl-2 with marked increase in the 
Bax protein expression levels in a time-dependent manner 
(Figure 5A). To investigate if the apoptosis was induced 
by FEO on human melanoma cells, FM94 cells treated 
with FEO (0, 7, 10 µg/ml) for 24 hours and the level of 
expression of the apoptotic markers (caspase 3, caspase 9, 
and PARP) were assessed. Figure 5B illustrates that FEO 
Figure 1: Cytotoxicity of FEO on B16-F10, FM94 and HNEM cells. (A) B16-F10 cells; (B) FM94 cells; (C) HNEM cells; 
(D) FM94 cells treated with FEO (A-Untreated cells; B-3 µg/ml; C-5 µg/ml; D-7 µg/ml; E-10 µg/ml; F- Dox 5 ug/ml) for 24 h and 
morphological image was photographed by EVOS image analyser; E: HNEM cells treated with FEO (A-Untreated cells; B-3 µg/ml; 
C-5 µg/ml; D-7 µg/ml; E-10 µg/ml; F- Dox 5 ug/ml) for 24 h and morphological image was photographed by EVOS image analyser. Data 
presented as mean ± SD of triplicates of three independent experiments. *Represents significant difference at p < 0.05 compared with 
control. **Represents significant difference at p < 0.01 compared with control. ***Represents significant difference at p < 0.001 compared 
with control. NS: Non significant. Scale bar indicates 10 um.
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significantly up regulated the cleaved caspase 3, caspase 9, 
and PARP expression in dose-dependent manner. Further 
time-dependent down regulation of MCL-1 a major anti-
apoptotic protein in melanoma was observed in FM94 
cells by FEO (10 µg/ml) treatment (Figure 5C). This data 
suggest that FEO induced apoptosis in both mice B16-F10 
and human FM94 carcinoma cells.
In vivo toxicity experiment
In order to assess the toxicity of FEO, mice were 
treated with a single dose of FEO (1200 mg/kg body 
weight) (i.p.) and observed for four weeks. Body weight 
and histology of major tissues (liver, kidney, brain, 
and heart) were analyzed. No significant difference 
in the body weight was observed in FEO treated mice 
compared to untreated control animals (Figure 6). 
Histological studies revealed that tissue sections from 
FEO-treated animals did not indicate any detectable 
pathologic abnormalities as examined by H&E staining. 
The liver showed normal hepatic lobular architecture, 
intact central vein with trapped red blood cells in a liver 
section from FEO treated animals. Kidney sections 
showed normal glomeruli, proximal and distal tubules, 
interstitium, and blood vessels. Brain and heart muscles 
normal morphology compared to untreated tissue sections 
(Figure 7).
Tumour remission by FEO
Melanoma tumour remission was observed in 
control and FEO treated tumour bearing mice. After 14 
days the size of tumour was reduced in FEO treated mice 
compared to untreated control animals (Figure 8). Pattern 
of tumour growth inhibition revealed that FEO treatment 
reduced the tumor size dose dependently.    
In vivo hepatoprotective efficacy of FEO
Efficacy of FEO on hematology of acetaminophen 
induced hepatic injured mice
Acetaminophen is well known to induce both acute 
and chronic hepatic failure. Therefore in this study we 
used acetaminophen to develop hepatic injury mice model 
and assessed the efficacy of FEO on complete blood count 
(CBC). The PVC (35.20 ± 1.93), WBC (6100 ± 556.78), 
neutrophil (78.20 ± 0.58), Hb (6.07 ± 0.18), MCHC 
(24.1 ± 1.74), and RBC (6.40 ± 0.092), was declined 
and lymphocytes (20.00 ± 0.50), MCV (133.4 ± 23), 
MCH (31.1 ± 4.37) counts were significantly (p < 0.05) 
increased in acetaminophen (750 mg/kg body weight) 
treated mice. Acetaminophen induced abnormality 
was significantly (p < 0.05) reversed by FEO (250 and 
500 mg/kg body weight) treatments (Table 1). 
Figure 2: FEO induced nuclear fragmentation in B16-F10 cells: B16-F10 cells were treated with different concentrations 
of FEO for 24 hours and stained with hoechest stain 33258. (A) Control; (B) 5 ug/ml; (C) 7 ug/ml; (D) 10 ug/ml. The nuclei were 
observed using fluorescence microscope (20 um).
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Figure 3: FEO induce DNA fragmentation in B16-F10 cells. B16-F10 cells were treated with 0, 5, 7 and 10 μg/ml for 24 hours. 
DNA was isolated resolved in agarose gel and examined by ethidium bromide staining.
Figure 4: Flow cytometric analysis of apoptosis: B16-F10 cells treated with FEO at 10 µg/ml for 24 h. Annexin-V FITC 
and propidium iodide staining were used to analyze apoptosis by flow cytometry. (A) Untreated cells showed 2–3% of cells in early or 
late apoptosis stage. (B) FEO treated cells, significant increase (*P < 0.05) in percentage distribution of cells in early (25%) and late (10%) 
apoptosis were observed.
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Efficacy of FEO on liver histology of acetaminophen 
induced hepatic injured mice
Drug induced hepatic injury markedly disturb the 
morphology and arrangement of cells within liver tissue. 
Acetaminophen (750 mg/kg body weight) treatment 
induced mild sinusoidal congestion, hepatocellular 
necrosis, focal damage around the central vein, feathery 
degeneration, loss of lobular architecture with damaged 
cellular outlines, hemorrhage, nuclei have become 
condensed, and microvesicular fatty change (Figure 9). 
These detrimental effects of acetaminophen were restored 
by pre treatment with FEO (250 and 500 mg/kg body 
weight) and silymarin (25 mg/kg body weight). 
Efficacy of FEO on biochemical parameters of 
acetaminophen induced hepatic injured mice
Alteration in biochemical parameters is clinical 
manifestation of systemic toxicities including 
hepatotoxicity. In this study, we measured the levels 
of toxicity associated biomarkers such as AST, ALT, 
ALK, bilirubin, protein, cholesterol, glucose, albumin/
globulin ratio and triglycerides in serum. Acetaminophen 
(750 mg/kg body weight) treated mice showed elevated 
levels of AST (118.50 ± 1.72, p < 0.05), ALT (114.00 ±2.67, 
p < 0.05), ALK (32.24 ± 1.96, p < 0.05), bilirubin 
(6.20 ± 0.63, p < 0.05), cholesterol (229.67 ± 0.75) and 
triglyceride (144 ± 14.4) whereas, the levels of protein 
(5.06 ±0.20, p < 0.05), glucose (90.66 ± 2.45), and albumin/
globulin ratio (4.36 ± 0.4) were decreased (Figure 10). 
Seven days of pre treatment with FEO (250 and 
500 mg/kg body weight) reversed the changes caused by 
acetaminophen and brought back the level of biochemical 
parameters to near normal control. 
Efficacy of FEO on Phase I and II drug metabolizing 
enzymes 
Drug metabolizing enzymes such as cytochrome 
p450 (Cytp450), cytochrome b5 (Cytb5) and glutathione-
s-transferase (GST) play pivotal role in detoxification 
of drugs. To develop FEO based drug formulation for 
melanoma treatment it is imperative to study efficacy of 
FEO on above mentioned enzymes. Administration of 
250 and 500 mg/kg body weight of FEO for seven days 
changed the levels of Cytp450 (2.7 ± 0.89, p < 0.001; 
3.9 ± 0.74, p < 0.001 respectively), Cytb5 (0.31 ± 0.19 
p < 0.01; 0.36 ± 0.14, p < 0.01 respectively), and GST 
(3.46 ± 1.08, p < 0.001; 3.89 ± 1.45, p < 0.001) significantly 
(Figure 11). Interestingly, treatment with FEO enhanced 
levels of these enzymes and this data clearly stated that 
FEO can retain hepatic physiological functions in particular 
detoxification. BHA was used positive diet control. 
Figure 5: Molecular mechanism of FEO induced apoptosis in B16-F10 and FM94 cells. (A) Bcl-2 and Bax protein expression 
of B16-F10 cells was determined after 24 and 36 h of treatment with 10 μg/ml of FEO; (B) Cleaved Caspase 9, Caspase 3 and PARP 
expression of FM94 cells was determined after 24 h treatment with 0, 7, 10 μg/ml of FEO. PC indicates positive control (5 μg/ml of 
doxorubicin); (C) MCL-1 expression of FM94 cells was determined after 3 h, 6 h, 12 h, and 24 h treatment with 10 μg/ml of FEO. Actin 
used for normalization of protein expression.  
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Figure 6: Effect of FEO on animal body weight: Data presented as mean ± SD (n = 8). Mice were treated with FEO 
(1200 mg/kg body weight) and observed for 30 days at weekly intervals.
Figure 7: In vivo of toxicity of FEO on major organs: Mice were treated with FEO (1200 mg/kg body weight). At the 
end of experimental period major organs such as brain, heart, liver and kidney were excised and stained with hemotoxylin and eosin. Scale 
bar indicates 10 μm.
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DISCUSSION
Surgical resection for early stage and drug 
(Ipilimumab and nivolumab) therapies for advanced 
stage of melanoma (metastasis) are often chosen by the 
oncologist but poor prognosis status and a decline in 
the patient’s survival accompanied with post treatment 
toxicities are major concerns. Diagnosis at early stage 
and developing tolerable agents for therapy are major 
challenges. Thus natural products have attracted attention 
in recent years for developing effective and safe anti-cancer 
drugs. About 36% of the low molecular weight compounds 
approved by the Food and Drug Administration (FDA) are 
natural products or their derivatives [27]. Epidemiological 
studies states that natural products including resveratrol, 
lycopene, dioscin and polyunsaturated omega-3 fatty acids 
(PUFA), play an indispensable role in preventing cancers 
with lower toxicities [28–32]. Frankincense is well known 
plant in Middle Eastern regions (Yemen and Oman), India 
and China. Since ancient times it is a common practice 
that inhaling of frankincense resin smoke, drinking of 
aqueous extract of frankincense resin and chewing fresh 
resin for healing various ailments. Different varieties of 
frankincense are available and some of them are edible 
too. In this study, we used hojari variety of frankincense 
resin (Boswellia sacra) which is edible and it is consumed 
by  local people. Frankincense extract has been studied 
for various biological activities in particular as an anti-
cancer agent and different forms of boswellic acids have 
been isolated as it is principal components [33]. The use of 
frankincense essential oil (FEO) in aromatherapy is well 
known and it is also reported its potential as anti-cancer 
agent against breast and pancreatic cancer in vitro [24, 
25]. Despite the  potential of FEO no concrete scientific 
evidence is available to translate this in to clinic. To explore 
further herein we report for the first time anti melanoma (in 
vitro and in vivo) efficacy and hepatoprotective capacity 
of FEO.     
Cytotoxicity of FEO was tested in B16-F10, FM94 
and HNEM cells. 24 h treatment with FEO significantly 
reduced the cell viability of B16-F10 and FM94 cells 
by sparing HNEM cells (Figure 1A–1C). This clearly 
indicates that FEO selectivity inducing cytotoxicity 
in carcinoma cells and not in normal cells.  To unravel 
the mechanism FEO mediated cell death, FEO treated 
cells were subjected to apoptotic analysis. Biochemical 
signatures accompanied with apoptosis include 
chromosomal DNA cleavage into inter-nucleosomal 
fragments, phosphatidylserine externalization and a 
number of intracellular substrate cleavages by specific 
Figure 8: Melanoma tumor remission efficacy of FEO: Data presented as mean ± SD (n = 6). Tumor was induced by 
transplanting B16F10 cells (5 × 105) in C57BL/6 mice. Tumor bearing mice treated with FEO (300 and 600 mg/kg of body weight) every 
two days for the total experimental period of 14 days and volume of tumor was measured. FEO 300 mg/kg bwt significantly (*p < 0.05) 
reduce the tumor volume on day 14 compare to control group. FEO 600 mg/kg bwt significantly (**p < 0.01, ***p < 0.001) reduced tumor 
burden on day 10, 12, and 14 compared to control group. 
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proteolysis [34]. Hoechest 33258 staining reveals that 
FEO treatment induced dose dependent nuclear damage 
in B16-F10 cells (Figure 2). Further experiment, indicated 
that FEO induces DNA damage in a dose dependent 
manner (Figure 3). It is well established that the principal 
component of FEO is α-pinene with other terpene 
mixtures [35]. These complex terpenes mixtures could 
intercalate with DNA to form adducts. Similarly α-pinene 
isolated from Schinus terebinthifolius Raddi induced DNA 
fragmentation in B16-F10 cells [36]. Previous works 
demonstrated that essential oils and other plant derived 
compounds can induce genomic DNA fragmentation in 
Figure 9: Efficacy of FEO on acetaminophen induced hepatic injury: Mice were divided into five groups (n = 6). 
(A) Untreated control: Mice received normal saline (0.9% v/w) i.p. for seven days. (B) Acetaminophen treated Acetaminophen (750 mg/
kg body weight) alone injected to mice i.p. for seven days to induce hepatic injury. (C) Frankincense 250 mg: Mice treated simultaneously 
with Acetaminophen (750 mg/kg body weight) and FEO (250 mg/kg body weight) for seven days. (D) Frankincense 500 mg: Mice treated 
simultaneously with Acetaminophen (750 mg/kg body weight) and FEO (500 mg/kg body weight) for seven days. (E) Silymarin 25 mg: 
Mice treated simultaneously with Acetaminophen (750 mg/kg body weight) and silymarin (25 mg/kg body weight) (positive drug control). 
After seven days of treatment period the liver of all the animals was excised and histology was carried out. Scale bar indicates 10 μm.
Table 1: Complete blood count: Values are expressed as mean ± SD (n = 8)
Parameters Group I Group II Group III Group IV
PVC 39.33 ± 0.67 35.20 ± 1.93 37.25 ± 3.04 33.75 ± 0.25
White blood cells (10 m/m3) 6500 ± 288.68 6100 ± 556.78 6500 ± 540.06 5000 ± 204.12
Lymphocytes 18.23 ± 1.76 20.00 ± 0.50* 20.40 ± 0.58 20.00 ± 0.82
Neutrophils 81.67 ± 1.76 78.20 ± 0.58* 79.50 ± 0.96 79.00 ± 0.86
Hb (g/dl) 8.10 ± 0.29 6.07 ± 0.18 6.93 ± 0.26 7.10 ± 0.70
MCV(μm3) 72.9 ± 7.97 133.4 ± 23 105.7 ± 15.6 88.0 ± 10.2
MCH (pg) 20.9 ± 2.21 31.1 ± 4.37 26.7 ± 4.04 22.7 ± 1.75
MCHC (%) 29.1 ± 1.88 24.1 ± 1.74 25.9 ± 2.31 26.7 ± 1.98
RBC (106 /mm3) 8.67 ± 0.072 6.40 ± 0.092* 7.47 ± 0.0821** 8.52 ± 0.079
Group I: Normal control treated with saline (0.9%); Group II: Hepatotoxic control group treated with acetaminophen 
(750 mg/kg body weight); Group III: Treated with FEO (250 mg/kg body weight) and acetaminophen (750 mg/kg body 
weight); Group IV: Treated with FEO (500 mg/kg body weight) and acetaminophen (750 mg/kg body weight). *Represents 
significant difference at P < 0.05 compared with control. **Represents significant difference at P < 0.01 compared with 
hepatotoxic control group.
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apoptotic cells [37, 38]. Though FEO treatment targeted 
the DNA in B16-F10 cells, it is imperative to understand 
apoptotic state of B16-F10 cells upon FEO treatment. 
Flow cytometric cell cycle analysis showed that FEO 
facilitates early apoptosis in B16-F10 cells than late 
apoptosis compared to untreated cells (Figure 4). Nuclear 
condensation and endonuclease G also translocates 
to the nucleus where it cleaves nuclear chromatin to 
produce oligonucleosomal DNA fragments which is 
referred to as early form of apoptosis [39, 40]. This is 
in agreement with our results where we observed FEO 
elicits extensive DNA damage with nuclear fragmentation. 
Induction of apoptosis is considered as a predominant 
therapeutic approach for various bioactive agents and 
natural products. Previous studies have indicated that 
Bcl-2 family proteins and pro-apoptotic proteins (Bax 
and Bak) play an important role in the intrinsic apoptotic 
pathway by regulation of mitochondria integrity [41]. 
While reduced Bcl-2 expression accompanied with high 
expression of Bax may promote apoptotic response to 
anticancer drugs, increased expression of Bcl-2 leads to 
resistance to chemotherapeutic drugs [42]. In our study, 
we found that FEO down regulates the expression of 
Bcl-2 with simultaneous up regulation of pro apoptotic 
Bax in B16-F10 cells (Figure 5A). FEO elicits apoptosis 
by down regulating the Bcl-2 which leads to formation 
of apoptosome in the cytosol and initiation of caspase 
signaling cascade. 
In order to evaluate the molecular mechanism of 
FEO induced apoptosis, we treated human melanoma 
cells (FM94) with FEO and assessed caspase 3, caspase 
9 and PARP expression.  The hallmark of apoptosis is 
upon receiving death signal in the form of ligands (Fas, 
Death receptor 3, 4, 5, and TRAIL) or drugs, proapoptotic 
proteins such as caspase 3, 8 and 9 undergo post 
translational modifications that include dephosphorylation 
and cleavage leading to their activation and formation 
of death inducing signaling complex and translocated 
in to mitochondria where apoptosis initiated [43]. 
Moreover caspase-3 activation is responsible for cleaving 
most apoptotic substrates such as poly-(ADP-ribose) 
polymerase (PARP) [44, 45]. In this study we observed 
profound expression of cleaved caspase 3, caspase 9 and 
PARP in FM94 cells upon FEO treatment (Figure 5B). 
Our data indicates that induction of apoptosis by FEO was 
caspase-dependent and appeared to be mediated by the 
Figure 10: Efficacy of FEO on biochemical parameters of acetaminophen induced hepatic injured mice: Values are 
expressed as Mean ± SD (n = 6). *p < 0.05 is considered significant when compared with group I; **p < 0.01 is considered significant 
when compared with group II by Dennett’s multiple comparison test. Group I: Untreated control fed orally with normal saline (0.9% v/w) 
5ml/kg body weight daily. Group II as hepatotoxic control treated with acetaminophen (750 mg/kg body weight). Group III and IV received 
FEO 250 and 500 mg/kg body weight respectively along with acetaminophen (750 mg/kg body weight) for seven days. Group V treated 
with Silymarin (25 mg/kg body weight) with acetaminophen (750 mg/kg body weight) for seven days. (A) AST, ALT, ALK. (B) Total 
bilirubin and total protein. (C) Cholesterol, glucose, and triglyceride. (D) Albumin/globulin ratio.
Oncotarget3482www.oncotarget.com
mitochondrial pathway. Similarly centipedegrass extract 
and docetaxel induced apoptosis in melanoma cells via 
caspase signaling [46, 47]. Studies found that MCL-1 
major anti-apoptotic protein was frequently overexpressed 
and identified as an important target in majority of human 
cancers [48]. MCL-1 is known to be critical for survival 
of melanoma cells under various stress conditions [49, 
50]. The expression of MCL-1 is also known to increase 
in melanoma with disease progression [51]. Reduction 
of MCL-1 expression weakens the link between pro- and 
anti-apoptotic Bcl-2 family proteins, such as Noxa/Mcl-1 
and Bim/Mcl-1, resulting in the release of pro-apoptotic 
Bcl-2 family proteins. Thus Mcl-1 plays a unique role in 
regulating apoptosis, as elimination of Mcl-1 is required at 
an early stage for induction of apoptosis [49, 50] Therefore 
we studied the efficacy of FEO on MCL-1 expression in 
FM94 cells. We found that FEO down regulates MCL-
1 time dependently (Figure 5C). This suggest a key 
role for MCL-1 in regulating apoptosis in FM94 cells 
induced by FEO. Similarly demethylzeylasteral and 
9, 11-dehydroergosterol peroxide induce apoptosis in 
melanoma cells by down regulating MCL-1 [52, 53].
Toxicity is a limitation of chemotherapy therefore 
the search for safer and system tolerated agents is always 
encouraged by the WHO. To determine whether 1200 mg/kg 
body weight of FEO treatment elicits changes in body 
weight and toxicities to normal major organs, we examined 
brain, heart, liver and kidney of treated and untreated 
groups of Swiss albino mice. Histological sections of these 
tissues from FEO treated mice did not show any detectable 
pathologic abnormalities as examined by H&E staining 
(Figure 7). The mouse melanoma cell B16F10, derived 
from C57BL/6 mice, is one of the most malignant cancers 
in mice and can serve as a good model of human melanoma 
to evaluate various treatments including vaccines [54–56]. 
Therefore in this study we used melanoma xenograft 
model by injecting B16F-10 cells in C57BL/6 mice. FEO 
(300 and 600 mg/kg body weight) treatment reduced tumor 
size significantly compared to untreated control animals 
(Figure 8). This is in agreement with our in vitro data. 
Figure 11: Efficacy of FEO on drug metabolizing enzymes of acetaminophen induced hepatic injured mice: Values 
are expressed as mean ± SD (n = 8) animals. *p < 0.05, **p < 0.01 represent significant changes against control. Group I: Untreated 
control and fed orally with distilled water daily for seven days. Group II: Mice treated with FEO 250 mg/kg body weight. Group III: Mice 
treated with FEO 500 mg/kg body. Group IV:  Mice treated with 0.75% BHA along with diet (positive control). (A) CytP450 and Cytb5, 
(B) GST. BHA – butylated hydroxyanisole; Cyt P450 – Cytochrome P450; Cyt b5 – Cytochrome b5; GST – Glutathione S-transferase.
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Generally essential oils are usually devoid of long term 
genotoxic risks and many of them show antimutagenic 
capacity that can be linked to anticarcinogenic activity. 
Furthermore, studies have demonstrated that essential oil 
constituents are very efficient in reducing the melanoma 
tumour volume or tumour cell proliferation by exerting 
apoptotic effects [57, 58].
Chemotherapy induced liver injury can cause 
necrosis, steatosis, fibrosis, cholestasis, and vascular 
injury [59]. Stage IV melanoma patient treated with 
ipilimumab and nivolumab exhibit elevation of hepatic 
injury biomarkers [13, 14]. Drug hepatotoxicity, is 
the leading cause of acute liver failure in the clinic 
worldwide [60]. Boswellia sacra extract shown to be 
hepatoprotective agent [61] however, FEO has not yet 
been reported for hepatoprotection effect. Acetaminophen 
is a classical hepatotoxin that is responsible for almost 
50% of all acute liver failure cases in the USA, the 
UK and many Western countries [60]. Hepatotoxicity 
is a direct liver injury caused by the toxic metabolite 
of acetaminophen [62]. In this study, acetaminophen 
(750 mg/kg body weight) was used to induce hepatic 
injury. Hepatoprotective efficacy of FEO (250 and 500 mg/
kg body weight) was studied on hepatic injured mice by 
assessing hematology (complete blood count), liver tissue 
histology, serum biochemical parameters, and phase I and 
II drug metabolizing enzymes. The analysis of blood cell 
count and Hb concentration are preliminary parameters to 
indicate abnormality. Pre treatment with acetaminophen 
altered the PVC, WBC, Lymphocytes, Neutrophils, Hb, 
MCV, MCH, MCHC%, and RBC. The administration 
of FEO reversed the altered counts in to normal level 
(Table 1). Our results evidenced that FEO can protect 
hepatic injury and associated blood cells abnormalities. 
Heavy dose of cancer drugs weakens the immune cells 
such as WBC, lymphocytes, and neutrophils which lead 
to their malfunction. A retrospective analysis of several 
ipilimumab Phase I–III trials in patients with advanced 
melanoma showed that immune related adverse events 
occurred in about 64.2% of treated patients and resulted 
in death [63]. Further Hb concentration along with RBC 
count determines the exchange of gases (O2 and CO2) to 
maintain homeostasis. FEO treatment restored blood cell 
counts and Hb level to normal values however; detail 
mechanistic study is required to delineate the role of FEO 
on blood components.  
Levels of transaminases (AST and ALT) and liver 
histopathological and morphometrical changes were 
used as indicators of hepatotoxicity [64]. In this study we 
analyzed AST and ALT levels in acetaminophen along 
with FEO treated mice. Treatment with FEO (250 and 
500 mg/kg body weight) reduced elevated levels of 
AST and ALT induced by acetaminophen administration 
(Figure 10). FEO could retain the liver structural 
integrity which was disturbed by acetaminophen because 
transaminases present in cytoplasmic location is released 
into the circulating blood only after structural damage [65, 
66]. ALK is a marker of intra or extra hepatic cholestasis, 
its synthesis increases and the enzyme is thus released into 
plasma under such conditions. Drug-induced liver injury 
may present with a cholestatic pattern conjugated with 
hyperbilirubinemia accompanied by an increase in ALK 
levels [67]. In our study we found that treatment with 
acetaminophen enhanced the levels of serum ALK and 
bilirubin (Figure 10). Administration of FEO significantly 
reduced the ALK and bilirubin levels. Hepatotoxic agents 
induced biliary obstruction which is responsible for 
hyperbilirubinemia and enhanced ALK levels [68]. Our 
data indicates that treatment with FEO could protect the 
billiary obstruction caused by acetaminophen. Liver is 
the primary site of the synthesis of plasma proteins [69], 
disturbances of protein synthesis therefore occur as a 
consequence of impaired hepatic function which will lead 
to a decrease in the plasma concentrations. In our study 
we observed that acetaminophen treatment significantly 
reduced serum protein concentration. Seven days of 
treatment with FEO restored the total protein levels. This 
data shows that impairment of hepatic function caused 
by acetaminophen has been rescued by FEO. Albumin 
and globulin (A/G) accounts for the largest proportion 
of serum protein and they are generated by the liver and 
A/G ratio acting as one of the biomarkers for evaluating 
liver function [70]. In this study, we found that treatment 
with acetaminophen diminished the level of A/G ratio. 
However, treatment with FEO brought back the A/G 
ratio to normal levels (Figure 10). It was reported that 
clinical observation of decrease of serum albumin levels 
in hepatic diseases are associated with destruction or loss 
of parenchymal elements [71]. In hepatic diseases gamma 
globulin may be produced in increasing amounts by the 
hepatic reticuloendothelial cells [72] which eventually 
alters A/G ratio. Failure to return to normal should raise a 
suspicion of delayed recovery or chronic active hepatitis. 
Our data reveals that FEO might protect parenchymal 
and reticuloendothelial cells to balance the A/G ratio. 
High triglyceride and cholesterol level in hepatic injury 
is the clinical manifestation of cholestasis or hepatitis. 
Generally, the level of plasma lipids tends to decrease with 
the severity of liver disease [73, 74]. This is in agreement 
with our results, where we found acetaminophen 
(750 mg/kg body weight) increased the level of cholesterol 
and triglycerides (Figure 10). The results evidenced that 
acetaminophen might induce reduction in lipase activity, 
which could lead to decrease in triglyceride hydrolysis and 
damage of hepatic parenchymal cells that subsequently 
leads to disturbance of lipid metabolism in the liver. 
Administration of FEO (250 and 500 mg/kg body weight) 
diminished levels of cholesterol and triglyceride. These 
finding showed that mechanism of lipid lowering effects 
of FEO might be attributed to an inhibitory activity on 
microsomal acyl coenzyme A: cholesterol acyltransferase 
enzyme. This enzyme is responsible for acylation of 
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cholesterol to cholesterol esters in the liver. Furthermore, 
level of glucose was measured in acetaminophen-
induced hepatic injured mice since maintenance of 
blood glucose requires the relatively intact liver cells to 
release glucose and hepatic insufficiency. The latter might 
leads to production of several abnormalities directly or 
indirectly associated with carbohydrate metabolism [75]. 
In the present study administration of FEO maintained 
the level of glucose similar to control level (Figure 10). 
It is suggested that FEO might protect glucose releasing 
hepatocytes to maintain the constant/normal glucose level.
Histopathological study of liver tissue revealed that 
normal control group showed normal hepatic cells with 
intact cytoplasm and well defined nucleus with restricted 
number of inflammatory cells (Figure 9A); whereas 
acetaminophen treated group, showed a central vein dilated 
along with hemorrhage, nuclei condensation, cytoplasmic 
membrane destruction. In addition, scattered lymphocyte 
and plasma cells were also seen around portal triad (Figure 
9B). The FEO and silymarin treated groups showed less 
damage with intact cytoplasm and nucleus and appeared 
to have normal hepatic cells (Figure 9C, 9D, and 9E). 
Phase I and Phase II drug metabolizing enzymes play an 
important role in converting toxic agents into non toxic and 
soluble substances. The rate limiting step in the activation 
and detoxification of chemical carcinogens and xenobiotics 
have been postulated to be dependent on the rate of 
reduction of cytochrome 450 (CytP450) substrate complex 
which in turn is dependent on the content of cytochrome 
b5 (Cytb5) and on the activity of NADPH cytochrome-c 
reductase [76]. Glutathione S-transferase (GST) is one of 
the detoxification systems in most human and animal tissues 
[77]. Organs with low levels GST are more susceptible to 
the toxic action of a variety of alkylating and therapeutic 
agents. In this study FEO (250 and 500 mg/kg body weight) 
treated mice showed increased levels of Cyt P450, Cyt b5, 
and GST (Figure 11). Therefore, it is suggested that FEO 
treatment mediated enhancement of Cyt P450, Cyt b5, and 
GST might act as a defense mechanism to protect the liver 
and probably other organs against the toxicity.
MATERIALS AND METHODS
Boswellia sacra essential oil preparation 
Certified Hojari grade Boswellia sacra gum resins 
were obtained from the local market. Essential oil was 
extracted by hydrodistillation method as described earlier 
[24]. Briefly, Boswellia sacra resins were loaded into 55° 
C water with a ratio of 1:2.5 (w/v), and mixed with an 
electromechanical agitator for 30–45 min or until a thick 
homogenous mucilage was formed. Temperatures of the 
hydrodistiller were monitored by an infrared thermometer; 
and pressures were recorded at the condenser terminal. 
To remove any residual water, collected Boswellia sacra 
essential oil (FEO) was immediately transferred into a 
–20° C freezer; and ice crystals were separated from the 
essential oil.
Cell lines and culture method
Mouse melanoma (B16-F10) cells were purchased 
from American Type Culture Collection, USA. Human 
melanoma cells (FM94) is kind gift from Dr. Sobia Kauser, 
University of Bradford, UK.  Human normal epithelial 
melanocytes (HNEM) purchased from Promo cells, UK. 
B16-F10 and FM94 cells were cultured in Roswell Park 
Memorial Institute (RPMI 1640) medium with 10% fetal 
bovine serum and 1% antibiotics (penicillin/streptomycin) 
and HNEM cells were cultured in Promo cell melanocytes 
growth medium. Cells were maintained in humidified cell 
incubator at 37° C and 5% CO2.
Drug preparation
Stock solution of FEO was prepared in dimethyl 
sulfoxide. Different concentrations of (3, 5, 7 and 10 µg/ml) 
were added in the cell culture medium.
MTT assay
B16-F10, FM94, HNEM cells (1 × 105/well) were 
seeded in 96 well plates (100 μL/well) and allowed to 
adhere firmly overnight in respective medium with 10% 
fetal bovine serum.  Then cells were treated with different 
concentrations (3, 5, 7 and 10 µg/ml) of FEO for 24 h. 
After 24h elapsed medium was removed and cells were 
incubated with MTT reagent (5 mg/mL) for 4 h and violet 
formazan crystals were dissolved in dimethylsulfoxide and 
absorbance was read at 540/690 nm. Absorbance of control 
(without treatment) was considered as 100% cell viability. 
Doxorubicin was used as positive drug control.
Fluorescence microscopic analysis of apoptosis
B16-F10, 1 × 105 cells/ml were seeded in 96 well 
plates (100 µ/well) and allowed to adhere firmly over night. 
The cells were then treated with different concentrations 
of FEO (5, 7 and 10 µg/ml). After 24 h treatment, 20 µl 
of trypsin was added into each well. Trypsinized cell 
suspension washed with phosphate buffered saline (PBS) 
and 25 µl cell suspension was transferred to glass slides. 
Hoechest 33258 (Sigma, St. Louis, MO, USA) staining 
solution was added to each suspension and then covered 
with a coverslip. The morphology of apoptotic cells was 
examined and visualized under a fluorescence microscope 
(Nikon Eclipse, Inc, Japan) at 400× magnification.  
DNA fragmentation by agarose gel 
electrophoresis 
Inter-nucleosomal cleavage of DNA was analyzed 
as described previously [78]. B16-F10 cells were seeded 
in 6-well plates at a concentration of 1 × 106 cells 
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per ml of medium. Cells were then treated with FEO 
(5, 7 and 10 µg/ml). Cells were harvested after 24 hours 
of treatment and DNA fragmentation was assessed by gel 
electrophoresis.
Annexin-V assay
B16-F10 (2 × 10 5cells/10 cm dish) cells were 
treated with 10 µg/ml of FEO for 24 h. Then cells were 
harvested by centrifugation, washed with ice-cold 
PBS, and then resuspended with ice-cold 70% ethanol 
overnight. The following day, cells were treated with 
10 μg/ml of RNase at 37° C, then spun down and stained 
with 40 µg/ml of propidium iodide (PI) and Annexin-
V-FITC for 30 min. The apoptotic state of cells was 
measured by flow cytometry (FACS, BD Bioscience).
Western blot analysis 
The whole cell lysate was prepared from B16-F10 
cells treated with FEO (10 µg/ml) for 24 and 36 hours, 
and FEO (0, 7, and 10 µg/ml) treated FM94 cells  for 
24 hours as described earlier [79]. Then whole cell 
lysate were resolved in a 10% SDS polyacrylamide 
gel electrophoretically and electro transferred onto a 
nitrocellulose membrane. The immunoblots were probed 
with Bcl-2, Bax, caspase 3 (cleaved), Caspase 9 (cleaved), 
and PARP antibodies and were visualized with the NBT/
BCIP chromogenic substrate. Further MCL-1 expression 
was determined in FM94 cells treated with FEO at 10 µg/ml 
for 3, 6, 12, 24 hours as described above. Antibodies 
purchased from Cell signaling technology, UK.
In vivo experiments
Animals 
The swiss albino and C57BL/6 mice were 
selected from a random breed colony maintained in 
the animal house of Jawaharlal Nehru Cancer Hospital 
and Research Center, Bhopal, India. The mice were 
housed in polypropylene cages containing sterile paddy 
husk (procured locally) as bedding and maintained 
under controlled conditions of temperature (23 ± 20° 
C), humidity (50 ± 5%) and light and dark (10–14 h) 
respectively. The animals are fed with standard mice 
feed (formula obtained from Cancer Research institute, 
Mumbai, India) and filtered acidified water ad libitum. 
Mice of either sex, 6–8 weeks old and weighing 22 ± 2 g, 
were selected from the above colony for the experiments. 
The study was carried out as per OECD guidelines for 
testing for chemicals under IAEC number JNCHRC/13/
IAEC/PN-185/B. All the experiments were conducted 
under the guidelines of Institutional Animal Ethical 
Committee (Project No.500/01/08/2016 /project 5 
/28/07/2019) and confirms to the guidelines set by WHO 
(World health organizations, Geneva, Switzerland and 
INSA, New Delhi, India.  
In vivo toxicity assessment 
Swiss albino mice were divided in to two groups 
(n = 16). Group I treated with vehicle (saline) and group 
II treated with FEO (1200 mg/ kg of body weight) 
intraperitoneally (i.p.) every week of total four weeks. 
Body weight was measured for 30 days on weekly basis. 
Histopathological analysis 
At the end of the experimental period, animals 
were euthanized by cervical dislocation and liver, kidney, 
brain, and heart tissues were dissected and examined by 
gross and microscopic anatomy. Then tissue sections were 
stained with hematoxylin and eosin staining as described 
earlier [80]. Microscopic evaluations were done by the 
pathologist.
Induction of tumour (melanoma) in mice 
Cell suspension of B16F10 cells (5 × 105) was 
implanted in C57BL/6 mice subcutaneously at the shaved 
part. The mice bearing the tumour were randomly divided 
into 3 groups with 6 mice in each group. The dosing was 
started when tumour has reached a mean diameter of 
100 mm3 and this day was designated as day 0.
Experimental design 
Mice (n = 18) were randomized into following 
three groups: Group I (Control (vehicle) treated with 
normal saline (0.9% v/w) i.p., Group II treated with FEO 
300 mg/kg of body weight (i.p), and Group III treated with 
FEO 600 mg/kg of body weight (i.p)  every two days for 
two weeks of experimental period. The tumour size was 
measured every alternate day using vernier calipers, and 
the tumour volume was calculated. 
Hepatoprotective activity 
Hematological analysis
Animals were randomized and divided into four 
groups (n = 8). Group I served as untreated control 
(treated with normal saline (0.9% v/w) i.p. daily for 
seven days). Group II as hepatotoxic control treated with 
acetaminophen (750 mg/kg body weight) i.p. for seven 
days. Group III received acetaminophen (750 mg/kg body 
weight) and FEO (250 mg/kg body weight) concurrently 
i.p. for seven days. Group IV received acetaminophen 
(750 mg/kg body weight) and FEO (500 mg/kg body 
weight) concurrently i.p. for seven days.  At the end of 
experimental period blood samples were collected via 
vein puncture into sterile sample tubes containing the 
anticoagulant, EDTA. Packed cell volume (PVC), White 
blood cells (WBC) count, Lymphocytes count, Neutrophils 
count, hemoglobin concentration (Hb), Mean corpuscular 
volume (MCV), Mean Corpuscular Hemoglobin (MCH), 
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Percent of Mean Corpuscular Hemoglobin Concentration 
(MCHC%), red blood cell (RBC) were analysed using an 
automated  analyser, Cell Dyne, model 331430, Abbott 
laboratories, IL, USA.
Determination of biochemical parameters and 
histology of liver
Animals were randomized and divided into five 
groups (n = 8). Group I served as untreated control 
(treated with normal saline (0.9% v/w) i.p. daily for 
seven days). Group II as hepatotoxic control treated with 
acetaminophen (750 mg/kg body weight) i.p., for seven 
days. Group III received aacetaminophen (750 mg/kg 
body weight) and FEO (250 mg/kg body weight) 
concurrently i.p. for seven days. Group IV received 
aacetaminophen (750 mg/kg body weight) and FEO (500 
mg/kg body weight) concurrently i.p. for seven days. 
Group V treated with acetaminophen (750 mg/kg body 
weight) and positive drug control Silymarin (25 mg/kg 
body weight) i.p., concurrently for seven days. At the end 
of experimental period blood samples were collected by 
puncturing retro-orbital plexus. The blood samples were 
allowed to clot for 45 min at room temperature. Serum was 
separated by centrifugation at 2500 rpm for 15 min at room 
temperature. Serum biochemical parameters such as serum 
glutamic oxaloacetic transaminase (AST), serum glutamic 
pyruvic transaminase, (ALT), serum alkaline phosphatase 
(ALK), bilirubin, protein, cholesterol, glucose, albumin/
globulin ratio, triglyceride were measured as described 
earlier. Furthermore, liver was excised from animals and 
subjected to histological analysis by hematoxylin and 
eosin staining method.
Determination of phase I and phase II drug 
metabolizing enzymes
Animals were randomized and divided into four 
groups (n = 8). Group I served as untreated control and 
fed orally with distilled water daily for seven days. 
Group II and III received FEO 250 and 500 mg/kg body 
weight (i.p), respectively for seven days. Group IV served 
as positive control and treated with 0.75% butylated 
hydroxyanisole (BHA) along with diet. At the end of 
experimental period livers were excised immediately and 
washed in ice cold normal saline, followed by 0.15 M 
Tris-Hcl (pH 7.4) blotted dry and weighed. A 10% (w/v) 
of homogenate was prepared in 0.15 M Tris-Hcl buffer. 
A part of homogenate after precipitating proteins with 
trichloroacetic acid (TCA) was used for analysis. 
Cytochrome P450 and Cytochrome b5
Cytochrome P450 was determined using the carbon 
monoxide difference spectra. Both cytochrome P450 
and cytochrome b5 content were assayed in microsomal 
suspension by the method of Omura and Sato [81], using 
an absorption coefficient of 91 and 185 cm2 M-1 m-1, 
respectively.
Glutathione S-transferase
Glutathione S-transferase (GST) activity was 
determined spectrophotometrically at 37° C as described 
earlier [82]. Briefly, the reaction mixture (1ml) contained 
0.334 ml of 100 mM phosphate buffer (pH 6.5), 0.033 ml 
of 30 mM CDNB and 0.033 ml of 30 mM of reduced 
glutathione. After pre incubating the reaction mixture for 
2 minutes, the reaction was started by adding 0.01 ml of 
diluted homogenate and the absorbance was followed for 3 
minutes at 340 nm. The specific activity of GST is expressed 
as μ moles of GSH-CDNB conjugate formed/min/mg protein 
using extinction co-efficient of 9.6 mM–1 cm–1. 
Statistical analysis 
The data represents mean ± STD. The Dunnett’s 
multiple comparison test was used for the analysis. 
P value < 0.001, <0.01, <0.05 was considered significant.
CONCLUSIONS
On the basis of above finding it is concluded that 
FEO exhibited in vitro anti-melanoma activity by reducing 
the viability in B16-F10 cell, FM94 cells and not in HNEM 
cells by the induction of apoptosis via caspase signaling 
and MCL-1 dependent pathway. Furthermore, FEO can 
reduce tumour size in C57BL/6 mice melanoma tumour 
model.  FEO can be most effective drug for prevention 
of hepatic injury along with improved hematological 
biochemical parameters, liver histology, phase I and phase 
II drug metabolizing enzymes. 
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